Literature DB >> 24377632

Epidemiology and survival of hepatocellular carcinoma in north-east Peninsular Malaysia.

Bachok Norsa'adah1, Che Ghazali Che Nurhazalini-Zayani.   

Abstract

The incidence of hepatocellular carcinoma (HCC) is relatively high in Southeast Asia. Globally, HCC has a high fatality rate and short survival. The objectives of this retrospective cohort study were to review the epidemiology and survival of HCC patients at a tertiary centre in north-east of Peninsular Malaysia. Subjects were adult HCC patients diagnosed by histopathology or radio-imaging. Secondary liver carcinoma was excluded. Kaplan Meier and multiple Cox proportional hazard survival analyses were used. Only 210 HCC cases from years 1987-2008, were included in the final analysis. The number of cases was increasing annually. The mean age was 55.0 (SD 13.9) years with male:female ratio of 3.7:1. Approximately 57.6% had positive hepatitis B virus, 2.4% hepatitis C virus, 20% liver cirrhosis and 8.1% chronic liver disease. Only 2.9% had family history and 9.0% had frequently consumed alcohol. Most patients presented with abdominal pain or discomfort and had hepatomegaly, 47.9% had an elevated α-fetoprotein level of 800 IU/ml or more, 51.9% had multiple tumors and 44.8% involved multiple liver lobes. Approximately 63.3% were in stage 3 and 23.4% in stage 4, and 82.9% did not receive any treatment. The overall median survival time was 1.9 months (95% confidence interval (CI): 1.5, 2.3). The 1-month, 6-month, 1-year and 2-year survival rates were 71.8%, 23.3%, 13.0% and 7.3% respectively. Significant prognostic factors were Malay ethnicity [Adjusted hazard ratio (AHR) 1.6; 95%CI: 1.0, 2.5; p=0.030], no chemotherapy [AHR 1.7; 95%CI: 1.1, 2.5; p=0.017] and Child-Pugh class C [AHR 2.6; 95%CI: 1.4, 4.9; p=0.002]. HCC in our study affected a wide age range, mostly male, in advanced stage of disease, with no treatment and very low survival rates. Primary prevention should be advocated in view of late presentation and difficulty of treatment. Vaccination of hepatitis virus and avoidance of liver toxins are to be encouraged.

Entities:  

Mesh:

Year:  2013        PMID: 24377632     DOI: 10.7314/apjcp.2013.14.11.6955

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  5 in total

1.  EHHM, a novel phenolic natural product from Livistona chinensis, induces autophagy-related apoptosis in hepatocellular carcinoma cells.

Authors:  Xinsheng Cheng; Feng Zhong; Kun He; Shibo Sun; Hongbo Chen; Jie Zhou
Journal:  Oncol Lett       Date:  2016-09-22       Impact factor: 2.967

Review 2.  The survival rate of hepatocellular carcinoma in Asian countries: a systematic review and meta-analysis.

Authors:  Soheil Hassanipour; Mouhebat Vali; Saber Gaffari-Fam; Hossein-Ali Nikbakht; Elham Abdzadeh; Farahnaz Joukar; Akram Pourshams; Afshin Shafaghi; Mahdi Malakoutikhah; Morteza Arab-Zozani; Hamid Salehiniya; Fariborz Mansour-Ghanaei
Journal:  EXCLI J       Date:  2020-01-13       Impact factor: 4.068

3.  Prediction of hepatocellular carcinoma risk in patients with type-2 diabetes using supervised machine learning classification model.

Authors:  Noor Atika Azit; Shahnorbanun Sahran; Voon Meng Leow; Manisekar Subramaniam; Suryati Mokhtar; Azmawati Mohammed Nawi
Journal:  Heliyon       Date:  2022-09-29

4.  Clinical Features and Overall Survival of Females with Hepatocellular Carcinoma: A Retrospective Study and Review of the Literature in the Association of Southeast Asian Nations.

Authors:  Sarita Ratana-Amornpin; Ratha-Korn Vilaichone; Muhammad Miftahussurur; Natsuda Aumpan; Kittipong Kaewkarnjanarat; Pongjarat Nun-Anan; Soonthorn Chonprasertsuk; Sith Siramolpiwat; Patommatat Bhanthumkomol; Bubpha Pornthisarn; Tomohisa Uchida; Varocha Mahachai
Journal:  Int J Womens Health       Date:  2021-07-22

Review 5.  Hepatocellular Carcinoma in Malaysia and Its Changing Trend.

Authors:  Ruksana Raihan; Amirah Azzeri; Fatiha H Shabaruddin; Rosmawati Mohamed
Journal:  Euroasian J Hepatogastroenterol       Date:  2018-05-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.